Methotrexate Roger Bellon Vial 50 Mg

Description

Active Ingredient and Mechanism of Action

The active ingredient in this medication is Methotrexate, a folate analog metabolic inhibitor. Methotrexate works by interfering with DNA production, effectively stopping cell growth and division. This mechanism is particularly effective against rapidly dividing cancer cells, as they are more sensitive to the damage caused by Methotrexate.

Methotrexate kills cancer cells by preventing them from making DNA. This is crucial because DNA is needed for cells to divide and grow. By inhibiting the production of DNA, Methotrexate effectively stops the cancer cells from growing and dividing. In addition to its direct action on cancer cells, Methotrexate may also help the body’s immune system fight the cancer, making it a powerful tool in cancer treatment.

Methotrexate Roger Bellon Vial 50 Mg Manufacturer

Methotrexate Roger Bellon Vial 50 Mg is manufactured by SANOFI WINTHROP INDUSTRIE, a reputable pharmaceutical company known for its high-quality products and commitment to patient care.

Uses and Indications

Methotrexate is used for the treatment of several neoplastic diseases, including:

1. Acute lymphoblastic leukemia as part of a combination chemotherapy regimen
2. Prophylaxis and treatment of meningeal leukemia
3. Non-Hodgkin lymphoma
4. Osteosarcoma as part of a combination chemotherapy regimen
5. Breast cancer as part of a combination chemotherapy regimen
6. Squamous cell carcinoma of the head and neck as a single agent
7. Gestational trophoblastic neoplasia as part of a combination chemotherapy regimen

In addition to its use in cancer treatment, Methotrexate is also employed in the management of other conditions, such as psoriasis and rheumatoid arthritis, due to its anti-inflammatory properties.

Research and Studies

Several studies have investigated the efficacy and safety of Methotrexate in various clinical settings. A study conducted in Turkey explored the antioxidant effects of rutin on methotrexate-induced hepatic oxidative stress. The study demonstrated that methotrexate caused oxidative stress in the liver and rutin had antioxidant effects on methotrexate-induced hepatic oxidative stress.

Another study examined the use of Methotrexate in the treatment of gestational trophoblastic neoplasia (GTN). The study found that Methotrexate was effective in treating low-risk GTN, with a response rate of over 80%. The study also highlighted the importance of careful patient selection and monitoring to ensure optimal outcomes.

Administration

Methotrexate Roger Bellon Vial 50 Mg is administered intravenously, typically in a hospital setting. The medication is given through a long plastic tube that goes into a large vein in the patient’s chest, and the tube remains in place throughout the course of treatment.

In some cases, Methotrexate may also be given as an oral tablet or liquid, intramuscular injection, or intrathecal injection (into the fluid around the spinal cord). The specific method of administration depends on the type of cancer being treated and the patient’s individual circumstances.

Patients may receive another drug called folinic acid after Methotrexate to help normal cells recover and reduce side effects. Folinic acid is a form of vitamin B9 that helps to counteract some of the toxic effects of Methotrexate on healthy cells.

Side Effects

Like other chemotherapy drugs, Methotrexate Roger Bellon Vial 50 Mg can cause a range of side effects, including:

1. Nausea and vomiting
2. Stomatitis (inflammation and sores in the mouth)
3. Leukopenia (decreased white blood cell count, increasing susceptibility to infections)
4. Fatigue
5. Skin rash
6. Loss of appetite

These side effects can vary in severity and duration depending on the dose and frequency of Methotrexate administration, as well as individual patient factors. Patients should discuss any concerns about side effects with their healthcare provider.

Dosage and Administration

The dosage of Methotrexate Roger Bellon Vial 50 Mg varies depending on the disease being treated and the patient’s individual response to treatment. Healthcare professionals should refer to the prescribing information for specific dosing guidelines.

For acute lymphoblastic leukemia, the recommended dosage varies from 10 to 5000 mg/m² intravenously. For high-dose Methotrexate Injection regimens, leucovorin rescue is used in accordance with high-dose methotrexate regimen guidelines. Lower doses (e.g., 20 to 30 mg/m²/week) may be used intramuscularly.

In the treatment of meningeal leukemia, only preservative-free Methotrexate Injection should be used for intrathecal use. The dosage and frequency of administration vary based on whether it is being used for treatment or prophylaxis.

For patients with low-risk gestational trophoblastic neoplasia (GTN), the usual dose is 30 mg/m² to 200 mg/m² or 0.4 mg/kg to 1 mg/kg intravenously or intramuscularly. For patients with high-risk GTN, the usual dose is 300 mg/m² over 12 hours as an intravenous infusion as a component of a multi-drug regimen.

In the treatment of psoriasis, the dosage is 10 – 25 mg once per week, not exceeding 30 mg per week. For rheumatoid arthritis, the dosage is 7.5 mg once weekly, or three doses each equal to 2.5 mg every 12 hours once weekly, with a maximum of 20 mg per week.

It is important to note that these are general guidelines, and the exact dosage should be determined by a healthcare professional based on the patient’s condition, response to treatment, and individual factors.

Contraindications and Precautions

Methotrexate Roger Bellon Vial 50 Mg is contraindicated in patients with severe renal impairment, severe liver disease, pre-existing blood dyscrasias, and known hypersensitivity to Methotrexate or any of its components. Healthcare professionals should exercise caution when administering Methotrexate to patients with impaired renal or hepatic function, as it may increase the risk of adverse effects.

Patients should be closely monitored for signs of toxicity, such as bone marrow suppression, hepatotoxicity, and pulmonary toxicity. Regular blood tests and monitoring of liver and kidney function are essential to ensure the safe and effective use of Methotrexate.

Conclusion

Methotrexate Roger Bellon Vial 50 Mg is a crucial medication in the treatment of various neoplastic diseases and other conditions. Its unique mechanism of action and potential to boost the immune system make it a valuable tool in the fight against cancer. However, it should only be used under the supervision of qualified healthcare professionals due to its potential side effects and contraindications.

As with any chemotherapy drug, the benefits and risks of Methotrexate treatment should be carefully weighed for each individual patient. Healthcare professionals should stay up-to-date with the latest research and guidelines to ensure the safe and effective use of this medication.

---

At a glance